Glasgow-based EnteroBiotix has completed a £19 million ($25 million) financing to advance its lead microbiome drug candidate, EBX-102-02, into Phase 2b development for irritable bowel syndrome with constipation (IBS-C).
The financing was led by life science investor Thairm Bio and the Scottish National Investment Bank, with participation from new and existing investors.
EnteroBiotix is a clinical-stage biopharmaceutical company building a leading position in full-spectrum microbiome therapeutics. The company says the round signals growing confidence in EBX-102-02 as a first-in-class, potentially disease-modifying therapy for IBS-C, a condition where unmet medical need has persisted for decades.
What does EnteroBiotix do?
EnteroBiotix develops microbiome therapies for gut health. EBX-102-02, the lead candidate, is a next-generation, orally delivered, full-spectrum investigational microbiome therapeutic, manufactured using EnteroBiotix's proprietary processing technologies. The drug is designed to deliver consistently high microbial diversity with a stable profile suitable for scalable manufacture.
In simpler terms, it is an oral product that aims to restore the diversity of the gut microbiome, rather than targeting a single bacterial strain in the way conventional gut treatments do. EBX-102-02 is not currently approved in any jurisdiction outside of clinical trials or regulated programmes.
What will the £19 million be used for?
The funding underwrites the Phase 2b RISE trial (Restoring Intestinal Symbiosis for Efficacy in IBS), a randomised, double-blind, placebo-controlled interventional trial enrolling approximately 300 patients with moderate-to-severe IBS-C across UK sites. First patient dosing is expected in Q2 2026, with topline efficacy data anticipated in H2 2027. The trial is registered on ISRCTN, the UK's clinical study registry, under reference ISRCTN15681288.
EnteroBiotix says the trial ranks among the largest interventional trials of a full-spectrum microbiome product ever conducted, and the largest ever in IBS. IBS-C is estimated to affect over 10 million people across the USA and Europe.
The RISE trial follows positive Phase 2a results from EnteroBiotix's TrIuMPH trial, a 122-patient study in IBS patients with constipation or diarrhoea, announced in January 2026. Dr James McIlroy, CEO of EnteroBiotix, said the new trial is designed to confirm the earlier signal. "Following the positive outcome of our Phase 2a TrIuMPH trial, which demonstrated clear efficacy signals of EBX-102-02 over placebo across key endpoints in patients with irritable bowel syndrome with constipation or diarrhoea, we are now commencing the largest ever full-spectrum microbiome therapeutic trial in IBS."
Why is this round significant for UK biotech?
EnteroBiotix is one of a small group of UK biotech companies advancing into late-stage clinical development with predominantly UK and Scottish capital behind them. The Scottish National Investment Bank has now backed the company across multiple rounds, and a specialist life science investor co-leading at this stage is a meaningful signal of institutional confidence in the science.
For UK biotech as a sector, the round is a useful counterpoint to the assumption that complex therapeutics need to relocate to the US to fund Phase 2b clinical work. A 300-patient interventional trial across UK sites, with capital from Scottish and specialist life science investors, says otherwise.
What this means for UK founders
For UK founders building in deep tech and biotech, EnteroBiotix offers two useful reference points, especially around founder-market fit.
First, demonstrating efficacy before raising bigger money. The £19M closed only after positive Phase 2a results in January 2026 had de-risked the science enough for a specialist life science lead investor to step in. For deep tech founders running long, expensive technical programmes, that pattern (clear data milestone, then a step-up round to fund the next stage) is the structural rhythm of how science-led companies attract capital.
Second, anchoring in a regional ecosystem. The Scottish National Investment Bank's repeat backing shows that regional and government-aligned capital can underwrite multiple rounds of a deep tech company without forcing relocation to London or San Francisco. EnteroBiotix sits alongside other UK life science raises like BioOrbit's £9.8M for in-space drug manufacturing and QV Bioelectronics' £4.5M. The UK secured second place globally in tech funding for 2025, and life sciences is a meaningful share of that activity.
We will update this story as the RISE trial progresses, with first patient dosing expected this quarter and topline data in H2 2027.
Building a UK biotech or deep tech startup, or thinking about how to fund the long path to clinical or commercial readouts? Join The Tech Founders community for case studies, founder interviews, and practical guides.
Related guides:
